Bank of America just raised its EUR/USD forecast
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) announced Wednesday that it has regained compliance with the continued listing requirements of the Nasdaq Capital Market. The company reported that on Tuesday, it was notified by Nasdaq’s Listing Qualifications staff that it now meets the necessary standards for continued listing.
Previously, on April 7, Alaunos Therapeutics received a notice from Nasdaq indicating non-compliance with Listing Rules 5550(b)(1), 5550(b)(2), and 5550(b)(3). These rules require a minimum of $2.5 million in stockholders’ equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations. According to its annual report for the year ended December 31, 2024, the company had reported stockholders’ equity of $2.06 million, falling short of the equity requirement.
Alaunos submitted a compliance plan within the 45-day period allowed under Nasdaq rules. In its quarterly report for the period ended June 30, 2025, the company reported stockholders’ equity of $3.66 million. Based on this updated figure, Nasdaq determined that Alaunos now complies with its listing requirements and has closed the matter.
The company’s common stock continues to trade on the Nasdaq Stock Market under the symbol TCRT.
This information is based on a statement from Alaunos Therapeutics in a recent SEC filing.
In other recent news, Alaunos Therapeutics, Inc. has been active in securing new funding and making strategic appointments. The company completed a $850,000 private placement of Series A-2 Convertible Preferred Stock, issuing 850 shares at $1,000 each. These shares come with a 10% annual dividend, payable in additional shares of the same series. Additionally, Alaunos Therapeutics raised approximately $2 million through a registered direct offering by selling 610,399 shares of common stock at $3.36 per share.
In terms of corporate governance, Alaunos announced the appointment of Michael A. Jerman to its board of directors. Mr. Jerman will also serve as chair of the Audit Committee, following the resignation of Dale Curtis Hogue and the appointment of Holger Weis as CEO. These developments reflect Alaunos Therapeutics’ efforts to strengthen its financial position and governance structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.